Inclusion Criteria:

- Biopsy proven squamous cell carcinoma of the head and neck, including of the oral
cavity, oropharynx, hypopharynx, or larynx

- Locally advanced, Stage III or IVB disease and a candidate for primary therapy using
chemotherapy and radiation with curative intent

- Patients with a diagnosis of 'unknown primary' will be eligible if chemoradiotherapy
is primary modality of treatment

- No previous chemotherapy, radiation, or surgery for the diagnosis of head and neck
cancer

- ECOG performance status 0 or 1

- Negative pregnancy test

- Hemoglobin >/= 8.0

- Absolute neutrophil count >/= 1500

- Platelet count >/= 100,000

- GFR > 50 mL/min

- Total bilirubin
- AST and ALT
- No other current malignancy, other than basal cell skin cancer, squamous cell skin
cancer, in situ cervical cancer, ductal or lobular in situ of the breast.

- Ability and willingness to give consent

- Subjects must in the opinion of the Investigator be capable of complying with the
protocol

Exclusion Criteria:

- Primary tumors of the nasopharynx, sinuses, and salivary glands

- Acute treatment for an infection or other serious medical illness within 14 days
prior to study entry

- Major surgery within 3 weeks prior to study entry

- Known hypersensitivity to cisplatin or cetuximab

- Patients who have any severe or uncontrolled medical conditions or other conditions
that could affect their participation in this study including: unstable angina,
serious uncontrolled cardiac arrhythmia, active or uncontrolled infectious disorder,
myocardial infarction
- Psychiatric illness that would limit compliance with study requirements